Cargando…

Interleukin-6 in Rheumatoid Arthritis

The role of interleukin (IL)-6 in health and disease has been under a lot of scrutiny in recent years, particularly during the recent COVID-19 pandemic. The inflammatory pathways in which IL-6 is involved are also partly responsible of the development and progression of rheumatoid arthritis (RA), op...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandolfi, Franco, Franza, Laura, Carusi, Valentina, Altamura, Simona, Andriollo, Gloria, Nucera, Eleonora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432115/
https://www.ncbi.nlm.nih.gov/pubmed/32718086
http://dx.doi.org/10.3390/ijms21155238
_version_ 1783571725276938240
author Pandolfi, Franco
Franza, Laura
Carusi, Valentina
Altamura, Simona
Andriollo, Gloria
Nucera, Eleonora
author_facet Pandolfi, Franco
Franza, Laura
Carusi, Valentina
Altamura, Simona
Andriollo, Gloria
Nucera, Eleonora
author_sort Pandolfi, Franco
collection PubMed
description The role of interleukin (IL)-6 in health and disease has been under a lot of scrutiny in recent years, particularly during the recent COVID-19 pandemic. The inflammatory pathways in which IL-6 is involved are also partly responsible of the development and progression of rheumatoid arthritis (RA), opening interesting perspectives in terms of therapy. Anti-IL-6 drugs are being used with variable degrees of success in other diseases and are being tested in RA. Results have been encouraging, particularly when anti-IL-6 has been used with other drugs, such as metothrexate (MTX). In this review we discuss the main immunologic aspects that make anti-IL-6 a good candidate in RA, but despite the main therapeutic options available to target IL-6, no gold standard treatment has been established so far.
format Online
Article
Text
id pubmed-7432115
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74321152020-08-24 Interleukin-6 in Rheumatoid Arthritis Pandolfi, Franco Franza, Laura Carusi, Valentina Altamura, Simona Andriollo, Gloria Nucera, Eleonora Int J Mol Sci Review The role of interleukin (IL)-6 in health and disease has been under a lot of scrutiny in recent years, particularly during the recent COVID-19 pandemic. The inflammatory pathways in which IL-6 is involved are also partly responsible of the development and progression of rheumatoid arthritis (RA), opening interesting perspectives in terms of therapy. Anti-IL-6 drugs are being used with variable degrees of success in other diseases and are being tested in RA. Results have been encouraging, particularly when anti-IL-6 has been used with other drugs, such as metothrexate (MTX). In this review we discuss the main immunologic aspects that make anti-IL-6 a good candidate in RA, but despite the main therapeutic options available to target IL-6, no gold standard treatment has been established so far. MDPI 2020-07-23 /pmc/articles/PMC7432115/ /pubmed/32718086 http://dx.doi.org/10.3390/ijms21155238 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pandolfi, Franco
Franza, Laura
Carusi, Valentina
Altamura, Simona
Andriollo, Gloria
Nucera, Eleonora
Interleukin-6 in Rheumatoid Arthritis
title Interleukin-6 in Rheumatoid Arthritis
title_full Interleukin-6 in Rheumatoid Arthritis
title_fullStr Interleukin-6 in Rheumatoid Arthritis
title_full_unstemmed Interleukin-6 in Rheumatoid Arthritis
title_short Interleukin-6 in Rheumatoid Arthritis
title_sort interleukin-6 in rheumatoid arthritis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432115/
https://www.ncbi.nlm.nih.gov/pubmed/32718086
http://dx.doi.org/10.3390/ijms21155238
work_keys_str_mv AT pandolfifranco interleukin6inrheumatoidarthritis
AT franzalaura interleukin6inrheumatoidarthritis
AT carusivalentina interleukin6inrheumatoidarthritis
AT altamurasimona interleukin6inrheumatoidarthritis
AT andriollogloria interleukin6inrheumatoidarthritis
AT nuceraeleonora interleukin6inrheumatoidarthritis